Camelot Portfolios LLC Invests $264,000 in Stryker Co. (NYSE:SYK)

Camelot Portfolios LLC bought a new position in shares of Stryker Co. (NYSE:SYK) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 881 shares of the medical technology company’s stock, valued at approximately $264,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Freedom Wealth Alliance LLC acquired a new stake in shares of Stryker during the fourth quarter worth $26,000. Quarry LP acquired a new stake in shares of Stryker during the first quarter worth $27,000. Rise Advisors LLC raised its position in Stryker by 692.9% during the third quarter. Rise Advisors LLC now owns 111 shares of the medical technology company’s stock valued at $30,000 after buying an additional 97 shares during the period. West Tower Group LLC acquired a new position in Stryker during the second quarter valued at $35,000. Finally, Cornerstone Planning Group LLC acquired a new position in Stryker during the second quarter valued at $38,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Stock Performance

SYK traded down $0.19 during midday trading on Thursday, reaching $350.81. The company’s stock had a trading volume of 284,963 shares, compared to its average volume of 1,287,877. The stock has a market cap of $133.47 billion, a P/E ratio of 42.70, a PEG ratio of 2.85 and a beta of 0.89. The company has a fifty day simple moving average of $347.58 and a 200 day simple moving average of $307.64. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $249.98 and a twelve month high of $361.41.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The company’s revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the firm posted $3.00 EPS. Research analysts expect that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.80 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is currently 38.79%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on SYK shares. Royal Bank of Canada reissued an “outperform” rating and set a $360.00 price target on shares of Stryker in a research report on Thursday, February 15th. Canaccord Genuity Group raised Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target on the stock in a research report on Wednesday, January 31st. Roth Mkm boosted their target price on Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Wells Fargo & Company boosted their target price on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a research note on Wednesday, January 31st. Finally, Citigroup boosted their target price on Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $335.27.

Insider Buying and Selling at Stryker

In other Stryker news, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares in the company, valued at approximately $1,317,414. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Stryker news, Director Ronda E. Stryker sold 201,146 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares in the company, valued at approximately $1,287,633,391.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO William E. Berry, Jr. sold 7,690 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the sale, the chief accounting officer now owns 3,675 shares of the company’s stock, valued at approximately $1,317,414. The disclosure for this sale can be found here. Insiders have sold 212,109 shares of company stock valued at $72,845,768 in the last 90 days. 5.90% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.